User login
AMSTERDAM – Dr. Roy S. Herbst cites post hoc analysis of the FLEX trial as a highlight of IASLC's World Conference on Lung Cancer. Investigators quantified EGFR number by an immunohistochemistry stain. Tumors with high EGFR levels had a significantly better response to cetuximab than did tumors with low EGFR levels. His second highlight is a pilot study with five patients that used PET imaging and labeled erlotinib to noninvasively quantify EGFR expression in tumor cells, precluding the need for biopsied tissue.
AMSTERDAM – Dr. Roy S. Herbst cites post hoc analysis of the FLEX trial as a highlight of IASLC's World Conference on Lung Cancer. Investigators quantified EGFR number by an immunohistochemistry stain. Tumors with high EGFR levels had a significantly better response to cetuximab than did tumors with low EGFR levels. His second highlight is a pilot study with five patients that used PET imaging and labeled erlotinib to noninvasively quantify EGFR expression in tumor cells, precluding the need for biopsied tissue.
AMSTERDAM – Dr. Roy S. Herbst cites post hoc analysis of the FLEX trial as a highlight of IASLC's World Conference on Lung Cancer. Investigators quantified EGFR number by an immunohistochemistry stain. Tumors with high EGFR levels had a significantly better response to cetuximab than did tumors with low EGFR levels. His second highlight is a pilot study with five patients that used PET imaging and labeled erlotinib to noninvasively quantify EGFR expression in tumor cells, precluding the need for biopsied tissue.